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1 
CYTISINE-LINKED ISOFLAVONOID 
ANTINEOPLASTIC AGENTS FOR THE 
TREATMENT OF CANCER 
CROSS-REFERENCE TO RELATED 
APPLICATION 
2 
cells and hence do not have the same energy demands. 
HSD 1784 inhibitors are useful agents for the treatment of 
cancers, such as colorectal cancer and prostate cancer. 
These and other advantages are satisfied, at least in part, 
5 by a cytisine-linked isoflavonoid compound or method of 
treating cancer by administering to a patient in need of such 
treatment an effective amount of a cytisine-linked isofla-
vonoid compound represented by formula (I): 
This application claims the benefit of U.S. Provisional 
Application No. 62/400,333 filed 27 Sep. 2016 the entire 
disclosure of which is hereby incorporated by reference 10 (I) 
herein. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 
This invention was made with govermnent support under 
Contract Nos. R21 CA139359 and ROI CAI 72379 awarded 
by The National Institutes of Health. The Govermnent has 
certain rights in the invention. 
TECHNICAL FIELD 
The present disclosure is directed to compounds having 
antineoplastic activity. In particular, the disclosure is 
directed to cytisine-linked isoflavonoids and use of such 
compounds to inhibit cancer cell growth, e.g., prostate or 
colorectal cancer, in a patient in need thereof. 
BACKGROUND 
15 
20 
8 
w 7 N-L--6 '.t\r-(X)n 5 
0 
or pharmaceutically acceptable salt thereof or a pharma-
ceutical composition thereof. In the cytisine-linked isofla-
vonoid represented by formula (I), Ar is an aryl or het-
eroaryl; n is an integer from 1 to 5; each Xis independently 
25 a halide, or alkoxy, or more than one X on Ar together form 
a cyclic ether structure; and wherein the compound is 
substituted on the C-2 position with H, alkyl, cycloalkyl or 
alkoxy, substituted on the C-5, C-6, C-7, and C-8 positions 
independently with H, hydroxy (OH), alkyl, cycloalkyl, 
30 alkoxy, Lis a substituted or unsubstituted di-radical linker 
group that links the cytisinyl group to either the C-5, C-6, 
C-7 or C-8 position. 
Metabolic dysregulation occurs in many human diseases, 
including diabetes, cardiovascular diseases and cancer, and 
raises important questions as to the molecular mechanisms 
conflating these diseases. Recent reports suggest that met-
formin, a first-line medication for the treatment of type II 
diabetes particularly in obese patients, reduces the risk of 
cancer through its presumed effects on adenosine mono-
phosphate (AMP)-activated protein kinase (AMPK). AMPK 
plays a central role in maintaining energy homeostasis 
through its regulation of downstream cellular events includ- 40 
ing mTOR signaling, lipid catabolism, and glucose metabo-
lism. The precise upstream events connecting metformin to 
AMPK may involve the serine/threonine kinase LKBl, 
which is also known as serine/threonine kinase-11 (STKl 1 ). 
Embodiments include one or more of the following fea-
tures individually or combined. For example, embodiments 
35 of the present disclosure include a cytisinyl-linked isofla-
vonoid represented by the following formula (II): 
(II) 
In connection with our development of antineoplastic 45 
agents, we selected the process of AMPK activation as an 
initial guide for evaluating new, natural product-derived 
agents such as semisynthetic isoflavonoids. We utilize the 
terminology "isoflavones" to describe naturally occurring 
compounds and "isoflavonoids" to describe compounds with 50 
both the naturally occurring pharmacophore and man-made 
chemical modifications not seen in nature. 
or pharmaceutically acceptable salt thereof or a pharma-
ceutical composition thereof, wherein the variables of n, X 
and L are as defined for formula (I). In this embodiment, L 
is a substituted or unsubstituted diradical linker group that 
links the cytisinyl group to the C-7 position in the isofla-
vonoid. In some embodiments, compounds of formula (I) or SUMMARY OF THE DISCLOSURE 
Advantages of the present disclosure include a cytisine-
linked isoflavonoid, or pharmaceutically acceptable salt 
thereof or pharmaceutically acceptable composition thereof, 
for the treatment of cancer. In particular, the compounds of 
the present disclosure are useful in treating conditions in 
which cancer cells, which have a rapacious need for energy, 
are deprived of a significant energy source, namely the 
degradation ( called beta-oxidation) of very long chain fatty 
acids. This degradation process proceeds in the peroxisome 
and requires the enzyme HSDl 784. Inhibition ofHSDl 784 
in normal cells is not problematic since these cells do not 
undergo continuous replication at the same rate as cancer 
55 (II) or pharmaceutically acceptable salts thereof can include 
wherein the C-2 substituent is hydrogen H or methyl; n is 1 
or 2, X is a halogen or an alkoxy group or two X together 
form a ring structure; the C-5 substituent is H, hydroxy or 
alkoxy; the C-6 substitutent is hydrogen H; the C-8 is H, 
60 methyl, alkyl or substituted alkyl. Linkers that are useful for 
the present disclosure include diradicals such as wherein L 
is a diradical linker group, such as -R2-, -R2Z-
(R'2)m -, -R2 Z-(R'2 )m -0-, where m is O or 1; R2 and 
R'2 are independently a C1_8 diradical alkyl such as 
65 -(CH2)n1- where nl is 1-8, e.g. 2-8; and Z represents 
either -(CH2 )n2-, -CH(OH)-, -CO-, ----C(O)O-, 
---OC(O)-, or -0-, wherein n2 is 1-4 
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Another aspect of the present disclosure includes admin-
istering to a patient in need of prostate or colorectal cancer 
treatment an effective amount of at least one compound of 
formula (I) or (II), or embodiments thereof, or pharmaceu-
tically acceptable salts thereof. 
In some embodiments, the administration can include a 
pharmaceutical composition including an effective amount 
of at least one compound of formula (I) or (II) or embodi-
ments thereof, or a pharmaceutically acceptable salt thereof, 
in combination with a pharmaceutically acceptable additive, 
e.g., a pharmaceutically acceptable carrier or excipient. 
4 
48 and 4C show the effects of cytisine-linked isoflavonoid 
lOc on the levels of Acetyl-CoA and ATP in cancer cells; 
FIGS. 4 D-F show the effects of cytisine-linked isoflavonoid 
lOc on respiration rates and ATP production in LS174T 
5 colon cancer cells. 
FIG. 5 is a schematic showing disruption of ATP produc-
tion from mitochondria or peroxisomes leading to increased 
levels of phosphorylated AMPK, which inhibits ACC-me-
diated lipogenesis and mTor-mediated cancer cell prolifera-
10 tion. 
Additional advantages of the present invention will 
become readily apparent to those skilled in this art from the 
following detailed description, wherein only the preferred 
embodiment of the invention is shown and described, simply 15 
by way of illustration of the best mode contemplated of 
carrying out the invention. As will be realized, the invention 
FIGS. 6A-6B relate to HSD17B4 depletion. FIG. 6A 
shows HSDl 784 depletion by shRNA activated AMPK in 
PC-3 cells and FIG. 68 shows HSD17B4 depletion by 
shRNA inhibited PC-3 cell proliferation. 
FIGS. 7A-7B show certain activity. FIG. 7A shows dehy-
drogenase activities of full-length and truncated HSDl 784 
and FIG. 78 shows hydratase activities of full-length and 
truncated HSDl 784. is capable of other and different embodiments, and its 
several details are capable of modifications in various obvi-
ous respects, all without departing from the invention. 
Accordingly, the drawings and description are to be regarded 
as illustrative in nature, and not as restrictive. 
BRIEF DESCRIPTION OF THE DRAWINGS 
Reference is made to the attached drawings, wherein 
elements having the same reference numeral designations 
represent similar elements throughout and wherein: 
FIGS. lA-lH show structures for isoflavonoids and cer-
tain effects thereof. In particular, FIG. lA shows natural 
isoflavones 1 and 2 and semisynthetic isoflavonoid 3; FIG. 
18 shows the synthesis of certain isoflavonoids. (Substituent 
key: a: R=H and X=H, b: R=H and X=OCH3 , c: R=H and 
X=Cl and d: R=CH3 and X=Cl. Reagent Legend: a, resor-
cinol, BF3 -Et20; b, DMF, BF3 -Et20, POC13 ; c, Ac2 0, 
K2 C03 , DMF; d, K2 C03 , BrCH2 CH2Br; e, piperazine or 
N-(2-hydroxyethyl)piperazine, NaI, K2C03 , DMF; f, 
cytisine, NaI, iPr2NH, DMF); FIGS. lC, lD and 1E show 
levels of phosphorylated AMPK and ACC following treat-
ment with isoflavonoids 3, 7, 8 and 10; FIG. lF shows the 
effects of cytisine-linked isoflavonoid lOc on AMPK sig-
naling and FIGS. lG and lH show three effects of cytisine-
linked isoflavonoid lOc on cancer cell proliferation. 
FIGS. 2A-2G show structures for cytisine-linked isofla-
vonoid and certain results thereof. In particular, FIG. 2A 
shows the synthesis of a biotinylated, cytisine-linked isofla-
vonoid 15d. (Reagent Legend: a, MCPBA; b, cytisine, 
EtOH, 90° C., pressure tube; c, Dess-Martin reagent; d, PEG 
hydrazide, CeCl3 ); FIGS. 28 and 2C show levels of phos-
phorylated AMPK and ACC following treatment with iso-
flavonoids; FIG. 2D shows purification of binding proteins 
of isoflavonoids AMPK activator; FIG. 2E shows validation 
of potential targets by Western blot; FIG. 2F shows 
HSDl 784 depletion by shRNA activated AMPK; and FIG. 
2G shows HSDl 784 depletion by shRNA inhibited LSI 74T 
cell proliferation. 
FIGS. 3A-3E relate to HSD17B4 protein domains. FIG. 
3A is a schematic diagram of HSDl 784 protein domains; 
FIGS. 38 and 3C show interactions ofbiotinylated, cytisine-
linked isoflavonoid 15d with full-length and truncated 
HSDl 784; FIG. 3D shows the effects of cytisine-linked 
isoflavonoid lOc on dehydrogenase activity of HSDl 784; 
FIG. 3E shows the effects of cytisine-linked isoflavonoid 
lOc on hydratase activity of HSDl 784. 
FIG. 8 shows cytisine-linked isoflavonoid lOc reduced 
20 respiration rate and ATP production of DLDl colon cancer 
cells. 
25 
FIGS. 9A and 98 show cytisine-linked isoflavonoid lOc 
inhibited respiration reduced respiration rate of PC-3 pros-
tate cancer cells. 
DETAILED DESCRIPTION OF THE 
DISCLOSURE 
The present disclosure relates to cytisine-linked isofla-
30 vonoids, or pharmaceutically acceptable salts or composi-
tions thereof, for use in inhibiting cancer cell growth. The 
unequivocal and unique biological target of these com-
pounds is an enzyme, hydroxysteroid 17~-dehydrogenase 4 
(HSDl 784), in the peroxisome that is responsible for the 
35 catabolism (i.e., degradation) of certain lipids. Specifically, 
this enzyme regulates sterol metabolism and most impor-
tantly, the catabolism of very long chain fatty acids (VL-
CFA). In general, catabolism of fatty acids with 20 or fewer 
carbons occurs in mitochondria, but these VLCFA (>22 
40 carbons) undergo initial degradation in the peroxisome and 
the shortened fatty acids then translocate to the mitochondria 
where their degradation is completed. The cytisine-linked 
isoflavonoids of the present disclosure selectively block this 
peroxisomal degradation and deprive cancer cells of the 
45 energy source generated by this degradative process that 
cancer cells need for their unregulated growth. 
In addition, it is believed that the cytisine-linked isofla-
vonoids serve as adenosine monophosphate (AMP)-acti-
vated protein kinase (AMPK) activators. AMPK serves as a 
50 sensor for maintaining cellular energy homeostasis and 
undergoes abnormal activation in human diseases such as 
cancer. The development of direct as well as indirect acti-
vators of AMPK represent a means for treating cancer. 
Hence, the cytisine-linked isoflavonoids of the present dis-
55 closure serve as AMPK activators that inhibit lipid catabo-
lism in the peroxisome, disrupt energy homeostasis, and 
depress cancer cell proliferation. These AMPK activators 
exert their effect by targeting a peroxisomal, multifunctional 
enzyme, HSDl 784 and selectively inhibiting the hydratase 
60 activity within this multifunctional enzyme. The HSDl 784 
inhibitors alter fatty acid profiles, reduce both acetyl CoA 
levels and ATP/AMP ratios, and activate AMPK when cells 
are treated with cytisine-linked isoflavonoids in the nano-
molar concentration range. 
FIGS. 4A-4F relate to fatty acid levels in cancer cells. In 65 
particular, FIG. 4A shows the effects of cytisine-linked 
isoflavonoid lOc on fatty acid levels in cancer cells; FIGS. 
Hence an advantage of the present disclosure includes 
cytisine-linked isoflavonoids, or pharmaceutically accept-
able salts thereof or pharmaceutically acceptable composi-
US 10,188,743 B2 
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tions thereof, for the treatment of conditions in which 
dysfunctional cells have extraordinary energy demands. In 
the present case where cancer cells require energy derived 
from the peroxisomal catabolism of very long chain fatty 
acids, these cytisine-linked isoflavonoids disrupt this energy 5 
supply and consequently disrupt cell proliferation. Cytisine-
linked isoflavonoids will be useful for treating a variant of 
cancers including colorectal cancer and prostate cancer 
In an aspect of the present disclosure, a patient suffering 
from cancer is treated by administering to such a patient in 10 
need of such treatment an effective amount of a cytisinyl-
linked isoflavonoid compound, or pharmaceutically accept-
able salt thereof or a pharmaceutical composition thereof. 
The cytisine-linked isoflavonoid compound can be repre-
15 
sented by the following formula (I): 
(I) 
6 
(II) 
wherein the variables of n, X and L are as defined for 
formula (I). In this embodiment, L is a substituted or 
unsubstituted diradical linker group that links the cytisinyl 
group to the C-7 position in the isoflavonoid. In some 
embodiments, compounds of formula (I) or (II) or pharma-
ceutically acceptable salts thereof, the isoflavonoids possess 
a hydrogen or CH3 group at C-2; the isoflavonoids possess 
8 
0 w 7 N-L--6 ,u-(X)n 
20 
a phenyl group at C-3 in which X is a fluoro, chloro, bromo 
or alkoxy group (-OR1 where R1 is an alkyl or cycloalkyl, 
e.g., a C1_8 alkyl), or more than one X on Ar together form 
a cyclic ether structure, e.g., X1 and X2 on Ar together form 
a ---0-R- or ---O-R---0- ring, where R is a diradical 
5 
0 
'--------y-----
isoflavonoid 
cytisinyl 
25 organo group); the isoflavonoids possess hydrogen H; 
hydroxy (OH); alkyl or cycloalkyl; e.g., methyl, ethyl, 
cyclopropyl; alkoxy (-OR1) an ---OCOR1 group such 
---OCOCH3 at C-5, C-6 and C-8; and the isoflavonoids 
possess a hydroxy group (OH) at C-7 that is alkylated by the 
wherein Ar represents aryl, e.g., phenyl, or heteroaryl, 
e.g., pyridinyl, diazinyl, pyrimidinyl, oxazolyl or imida-
zolyl. The variable n represents the number ofX groups on 
30 linker L, which is a substituted or unsubstituted diradical 
group that links the cytisinyl moiety to the isoflavonoid 
moiety. 
While it may be possible for compounds of the present 
disclosure to be administered without an additive, it is 
Ar and can be an integer from 1 to 5. Each X, e.g., X1, X2, 
X3 , X4 , and/or X5 , is independently a halide, e.g., a fluoro, 
chloro, or bromo, or alkoxy (---OR1 where R1 is an alkyl or 
cycloalkyl, e.g., a C1_8 alkyl), or more than one X on Ar 
together form a cyclic ether structure, e.g., X1 and X2 on Ar 
together form a ---0-R- or ---O-R---0- ring, where R 
35 preferable to present them as a pharmaceutical composition. 
According to a further aspect, the present disclosure pro-
vides a pharmaceutical composition comprising a compound 
or mixture of compounds of Formula (I) and/or Formula (II) 
or a pharmaceutically acceptable salt, solvate, or hydrate 
is a diradical organo group. Examples of such groups 
include a methylenedioxy, dimethylenedioxy, etc. The iso-
flavonoid moiety can be substituted at each of its C-2, C-5, 
C-6, C-7, C-8 positions, provided at least one of C-5, C-6, 
40 thereof, together with one or more pharmaceutically accept-
able additives, e.g., a pharmaceutically acceptable carrier or 
excipient and optionally one or more other therapeutic 
ingredients. The additive(s) must be "acceptable" in the 
sense of being compatible with the other ingredients of the 
45 formulation and not deleterious to the recipient thereof. The 
term "pharmaceutically acceptable carrier" includes 
vehicles and diluents. 
C-7 or C-8 is bonded to L. In certain embodiments, the 
cytisinyl moiety is linked to the isoflavonoid by linker L at 
the C-7 position. The substituent on C-2, C-5, C-6, C-7, C-8 
can independently be the same or different and include 
hydrogen (H); hydroxy (OH); alkyl or cycloalkyl; e.g., 
methyl, ethyl, cyclopropyl; alkoxy (---OR1) an -OCOR1 50 
group such -OCOCH3 . L is a substituted or unsubstituted 
diradical group that links the cytisinyl moiety to the isofla-
vonoid moiety at the C-7 position. Linkers that are useful for 
the present disclosure include diradicals such as wherein L 
is a diradical linker group, such as -R2-, -R2Z- 55 
(R'2 )m -, -R2Z-(R'2)m ---0-, where m is O or 1; R2 and 
R'2 are independently a C1_8 diradical alkyl such as 
-(CH2)n1- where nl is 1-8, e.g. 2-8; and Z represents 
either -(CH2)n2-, -CH(OH)-, -CO-, -C(O)O-, 
-OC(O)-, or-0-, wherein n2 is 1-4. In an embodiment 60 
of the present disclosure, L is -(CH2)n1 (CH2)n20-, 
-(CH2)n1CH(OH)(CH2)n10-, and -(CH2)n1CO 
(CH2)n10-. 
Embodiments of the present disclosure include a cytisine-
linked isoflavonoid, or pharmaceutically acceptable salt 65 
thereof or a pharmaceutical composition thereof, repre-
sented by the following formula (II) 
The compounds and/or compositions of the present dis-
closure are useful for treating animals, and in particular, 
mammals, including humans, as patients. Thus, humans and 
other animals, and in particular, mammals, suffering from 
hyperproliferative disorders such as cancer, can be treated 
by administering to the patient an effective amount of one or 
more of the cytisinyl-linked isoflavonoids according to the 
present disclosure, or a pharmaceutically acceptable salt 
thereof, optionally in a pharmaceutically acceptable addi-
tive, either alone, or in combination with other known 
pharmaceutical agents. Treatment according to the present 
disclosure can also be by administration of the compounds 
and/or compositions of the present disclosure in conjunction 
with other conventional cancer therapies, such as radiation 
treatment or surgery or administration of other anti-cancer 
agents. 
In the course of developing the cytisine-linked isofla-
vonoids of the present disclosure and identifying their 
mechanisms of HSD 1784 inhibition and concomitant 
AMPK activation, we screened a library of semisynthetic 
US 10,188,743 B2 
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isoflavonoids that possess the pharmacophore found in these 
natural products but that also possess structural modifica-
tions not seen in nature. The rationale behind the selection 
8 
the biotin moiety sufficiently far from the isoflavonoid to 
permit capture by steptavidin. Balancing these requirements 
led us to synthesize a biotinylated analog with a longer 
linker L than the two carbons found in 1 Oc in order to of isoflavonoids for this screening program rested on iso-
flavones, such as daidzein (1) and genistein (2) (FIG. lA), 
that appear in dietary supplements with alleged health 
benefits including claims for the treatment of cancer. We 
synthesized and screened semisynthetic isoflavonoids and 
identified a specific subgroup of cytisine-linked isoflavones 
as potent AMPK activators with a unique cancer-relevant, 
peroxisomal enzymatic target, namely HSD17B4. 
5 provide adequate separation between the streptavidin-biotin 
complex and the complex between 1 Oc and its target. In 
addition, we needed a functional "handle" on this longer 
linker for the attachment of the biotin tag. After some 
experimentation to find the appropriate combination of 
Structure-activity studies focused on modifications at C-2, 
10 linker length and covalent attachment site, we found that the 
alkylation of the isoflavonoid 3d with 6-bromo-1-hexene 
furnished the 5-hexenyloxyisoflavonoid (1 ld), and treat-
ment of lid with meta-chloroperoxybenzoic acid led to the 
epoxide 12d (FIG. 2A). Alkylation of 12d with cytisine (9) 
C-7 and the C-4', which is the para-position in the isofla-
vonoid scaffold 3. Synthesis of these isoflavonoids 3 
required the condensation of resorcinol with arylacetic or 
heteroarylacetic acids 4 to furnish the deoxybenzoins 5, and 
the subsequent condensation of 5 with either N,N-dimeth-
ylformamide and boron trifluoride etherate or with acetic 
anhydride and potassium carbonate to afford the isofla-
vonoids 3 (FIG. 18). Preliminary screening identified the 20 
most promising isoflavonoids 3 as those with hydrogen or 
methyl groups at C-2, para-chlorophenyl groups at C-3, and 
hydroxyl groups at C-7. Most isoflavonoids exhibited 
AMPK activation only at relatively high 30 µM concentra-
tions (representative sample in FIG. lC). Isoflavonoids 3c 25 
and 3d were the most active AMPK activators and displayed, 
15 gave the intermediate alcohol 13d; oxidation with Dess-
Martin's reagent secured the ketone 14d; and condensation 
with a PEG biotinylated hydrazide afforded the cytisinyl-
linked isoflavonoid 15d. The intermediate alcohol 13d and 
as expected, modest activation of acetyl CoA carboxylase 
that lay downstream of AMPK. 
the ketone 14d as well as the biotinylated cytisinyl-linked 
isoflavonoid 15d activatedAMPK (FIGS. 28 and 2C) in the 
10-30 µM range, which was sufficient to proceed with a 
pull-down assay. As controls to establish the requirement for 
both the cytisine and isoflavone moieties for AMPK activa-
tion, we also synthesized the cytisinyl-substituted alcohol 16 
and ketone 17 (FIG. 2A) in which a phenoxy group replaced 
the isoflavonoid, and we established that 16 and 17 were 
inactive as AMPK activators (FIG. 28). 
Identification of the direct target of these AMPK activa-
tors involved incubation of 15d with LSI 74T cell lysates and 
a subsequent pull-down assay using biotinylated 15d bound 
to streptavidin beads. The binding proteins were eluted with 
2.5 mM biotin and analyzed by 4-12% SDS-PAGE gel using 
colloidal blue staining (FIG. 2D). We identified two specific 
bands (Fl and F2) in the 15d-containing sample compared 
with the control samples containing only beads or only 
beads and biotin. These two bands were excised from gels 
and analyzed by NanoLC-ESI-MS/MS. The band Fl (FIG. 
2D) contained two proteins: [1] peroxisomal hydroxysteroid 
17-dehydrogenase-4 (HSDl 784); and [2] mitochondrial 
methylcrotonoyl-CoA carboxylase subunit alpha (MCCA). 
The band F2 also matched HSD17B4. 
We validated these results by Western blotting using 
antibodies against HSDl 784 and MCCA. We discounted the 
MCCA protein, which appeared in both 15d-containing 
sample and in the control sample, as a non-specific binding 
protein of the stepavidin complex with 15d. We focused on 
the multifunctional HSDl 784 protein, which appeared only 
in the 15d-containing sample (FIG. 2E), as a specific binding 
protein of the biotinylated, cytisine-linked isoflavonoid 15d 
Additional modifications that improved potency in 
AMPK activation included the attachment of various 30 
w-aminoalkyl groups to the C-7 hydroxyl group in 3 through 
spacers of various carbon-chain lengths. The alkylation, for 
example, of the isoflavonoids 3 with 1,2-dibromoethane 
secured the 7-(2-bromoethoxy)isoflavonoids 6, and the sub-
sequent condensation of 6 with either piperazine or N-(2- 35 
hydroxyethyl)piperazine led to the (piperazin-1-yl)ethoxy)-
substituted isoflavonoids 7 and 8, respectively (FIG. 18). 
These piperazine-substituted isoflavonoids 7 and 8 activated 
AMPK at lower concentrations (i.e., 10 µM) than those at 
which the unmodified isoflavonoids 3 (FIG. lD versus lC) 40 
were active. In addition to screening similarly substituted 
isoflavonoids bearing other monocyclic, heterocyclic 
amines (data not shown), we examined naturally occurring 
alkaloids as potential partners for the N-alkylation of 7-(2-
bromoethoxy)isoflavonoids 6. In particular, the covalent 45 
coupling of 6 with cytisine (9) led to the 7-(2-cytisiny-
lethoxy)isoflavonoids 10 that displayed potent AMPK acti-
vation in the low µM range (FIG. lE). Thus, through a 
logical series of SAR studies, we arrived at the potent 
cytisine-linked isoflavonoids. 
We next tested the activity of these potent cytisine-linked 
isoflavonoids such as lOc (FIG. 18 in which the letter c 
designates the following substitution pattern: R=H and 
X=Cl) on the proliferation of cancer cells. We treated PC-3 
prostate cancer cells and LS 17 4 T colon cancer cells with 1 Oc 55 
and analyzed a panel of markers by Western blotting (FIG. 
lF). Treatment with 1 Oc activated AMPK in both cell lines, 
and induced appreciable ACC phosphorylation, a key regu-
lator in lipid biosynthesis downregulated during rapid 
growth. In addition, treatment with lOc also inhibited the 60 
phosphorylation of p70 and S6, key components of the mTor 
pathway important for cell growth. As a result, the cystisine-
linked isoflavonoid lOc significantly inhibited the prolifera-
tion of both PC-3 and LSI 74T cells (FIGS. lG and lH). 
50 in the peroxisome. The multifunctional nature of HSD 1784 
included two of the four enzymatic activities required for the 
beta-oxidation of very long-chain fatty acids (VLCFA) in 
the peroxisome. Proteolytic cleavage of HSDl 784 gener-
To identify the molecular target, we sought a biotinylated 65 
analog of this cytisine-linked isoflavonoid lOc that retained 
biological activity as an AMPK activator and that positioned 
ated a N-terminal 32-kD fragment possessing a,~-dehydro-
genase activity and a C-terminal 45-kD fragment with 
hydratase activity as well as a solute-carrier-protein-2-like 
domain (SCP2L). The HSD17B4 antibody (GeneTex) rec-
ognized the full-length and the C-terminal fragment (FIG. 
2E). 
We presumed that disruption ofVLCFA processing in the 
peroxisome by inhibitors of HSDl 784 affected energy 
homeostasis, particularly in cancer cells, and triggered 
AMPK phosphorylation. To validate HSD17B4 as a direct 
target of these isoflavonoid inhibitors leading to AMPK 
activation, we knocked down HSDl 784 using shRNA in 
LS174T colon cancer cells and PC-3 prostate cancer cells. 
As expected, HSDl 784 depletion increased AMPK phos-
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phorylation (FIGS. 2F and 6A). Depletion ofHSDl 784 also 
significantly inhibited the proliferation of both LSI 74T and 
PC-3 cells (FIGS. 2G and 68). These results were consistent 
with results seen in the treatment of these same cells either 
with lOc (FIGS. lF-H) or with 13d, 14d or 15d (FIGS. 5 
28-C) and these results suggested that these cytisine-linked 
isoflavonoids activated AMPK by directly targeting 
HSD17B4. 
10 
rate of mitochondrial beta-oxidation increased, and as we 
observed, the level of all fatty acids, not just the VLCFA, 
was decreased. 
We further characterized the effects of cytisine-linked 
isoflavonoid 1 Oc on energy metabolism using a Seahorse XF 
assay (FIG. 4D-F) that measured oxygen consumption rate 
(OCR), which was an indicator of mitochondrial respiration, 
and measured extracellular acidification rate (ECAR), which 
was largely the result of glycolysis. We found that cytisine-We next sought to delineate if these cystisine-linked 
isoflavonoid inhibitors were selective for one of the two 
enzymatic activities, either the a,~-dehydrogenase or 
hydratase activity, found in HSD 1784. We generated a panel 
of truncated HSDl 784 constructs and purified these trun-
cated proteins as well as the full-length protein from E. coli 
(FIG. 3A). We evaluated the binding of 15d to these con-
structs using the streptavidin bead-based pull-down assay. 
The full-length HSDl 784, but not the C-terminus-truncated 
fragments N318 and N634, interacted with 15d (FIG. 38). 
However, the N-terminus-truncated fragment C919 also 
strongly bound 15d (FIG. 3C), which suggested that the 
isoflavonoids bound to the C-terminus of HSDl 784 and 
inhibited selectively the hydratase activity of HSDl 784. 
10 linked isoflavonoid lOc significantly reduced the respiration 
rates of LSI 74T cells and reduced the levels of ATP pro-
duction in both respirometry (OCR) and extracellular acidi-
fication rate (ECAR) assays. Similar results were found in 
DLD-1 colon cancer cells and PC-3 prostate cancer cells 
15 (FIGS. 8 and 9). These OCR findings were consistent with 
the prior evaluation of these cytisine-linked isoflavonoids 
that targeted the hydratase activity in HSDl 784, inhibited 
VLCFA beta-oxidation, depressed acetyl CoA generation, 
decreased the ratio of ATP/ AMP, and triggered AMPK 
20 activation (FIG. 5). 
We acquired further evidence along these lines through 
studies using the N-terminal a,~-dehydrogenase and C-ter-
minal hydratase fragments of HSD 1784 as well as the 25 
full-length protein. We evaluated the a,~-dehydrogenase 
activity using DL-3-hydroxylbutyryl-CoAas a substrate and 
the conversion of NAD+ to NADH as a readout. We con-
EXAMPLES 
The following examples are intended to further illustrate 
certain preferred embodiments of the invention and are not 
limiting in nature. Those skilled in the art will recognize, or 
be able to ascertain, using no more than routine experimen-
tation, numerous equivalents to the specific substances and 
procedures described herein. 
Materials and Characterization. Chemicals were pur-
chased from Sigma Aldrich (Milwankee, Wis.) or Fisher 
Scientific (Pittsburgh, Pa.) or were synthesized according to 
literature procedures. Hydrazide-PEG4 -biotin was pur-
chased from Thermo Fisher Scientific (Florence, Ky.). Sol-
35 vents were used from commercial vendors without further 
comitantly measured the hydratase activity using crotonoyl-
CoA as a substrate and the diminished ultraviolet absorption 30 
of the a,~-unsaturated thioester chromophore as readout. 
The full-length protein, as expected, had both enzyme 
activities (FIGS. 7A and 78). The C-terminal-truncated 
fragments N318 and N634 but not the N-terminal-truncation 
fragment C919 had a,~-dehydrogenase activity (FIG. 7A). 
The C-terminal fragment N634 and the N-terminal fragment 
C919, but not the C-terminal fragment N318, had hydratase 
activity (FIG. 78), as summarized in FIG. 3A. These results 
were consistent with previous reports about the interlocking 
roles of the different domains in HSDl 784. We tested the 40 
effects of cytisine-linked isoflavonoid 1 Oc on each enzyme 
activity and found that lOc had no effect on the a,~-
dehydrogenase activity (FIG. 3D) but significantly inhibited 
the hydratase activity (FIG. 3E). In summary, cytisine-
linked isoflavonoids specifically bound the C-terminus of 45 
HSDl 784 and selectively inhibited the hydratase activity of 
this multifunctional HSD 1784 enzyme. 
To test the effects of these HSDl 784 inhibitors on lipid 
metabolism, we analyzed the fatty acid profiles of LSI 74T 
colon cancer cells after treatment with cytisine-linked iso- 50 
flavonoid 1 Oc, although we recognized that fatty acid 
catabolism occurred in interdependent processes in two 
different organelles at different rates. Reflective of this 
complexity, we found that cytisine-linked isoflavonoid lOc 
reduced the levels of a number of fatty acids (FIG. 4A), not 55 
just the long-chain fatty acids. Collectively, this outcome 
suggested that these cytisine-linked isoflavonoids activated 
AMPK through their effects on the hydratase activity in 
HSDl 784 and broad effects on fatty acid catabolism 
involved a combination of diminished acetyl CoA levels 60 
arising out of VLCFA and energy homeostasis in cancer 
cells. Consistent with this hypothesis, treatment with 
cytisine-linked isoflavonoid lOc decreased the levels of both 
acety 1 Co A and ATP (FI GS. 4 B and 4C) in LS 17 4 T cancer 
cells. We assumed that inhibition of HSDl 784 affected 65 
VLCFA and depressed the levels of certain long-chain fatty 
acids destined for the mitochondria. As a consequence, the 
purification unless otherwise noted. Nuclear magnetic reso-
nance spectra were determined on a Varian instrument (1 H, 
400 MHz; 13C, 100 Mz). High resolution electrospray 
ionization (ESI) mass spectra were recorded on a Thermo-
Scientific Q Exactive Orbitrap mass spectrometer. Resolu-
tion was set at 100,000 (at 400 m/z). Samples were intro-
duced through direct infusion using a syringe pump with a 
flow rate of 5 µUmin. Purity of compounds was greater than 
95% as established using combustion analyses determined 
by Atlantic Microlabs, Inc. (Norcross, Ga.). Compounds 
were chromatographed on preparative layer Merck silica gel 
F254 unless otherwise indicated. Methods for the synthesis 
of isoflavonoids were described in the Supplemental Mate-
rial section. 
Cell Culture. LS74T colon cancer cells were cultured in 
MEM/EBSS (Hyclone SH30024) and PC-3 prostate cancer 
cells were cultured in DMEM/F-12 HAM Mixture (Sigma 
D8437) containing 10% Fetal Bovine Serum (Atlanta Bio-
logical S11150). Cells (3.5xl04 cells per well) were split into 
12-well plates. After 24 h, 10 µM of each compound were 
added to each well. DMSO was used as a control. Each 
experiment was done in triplicate. Cell viability and number 
were analyzed using the Vi-Cell XR Cell Viability Analyzer 
(Beckman Coulter). To knock-down HSDl 784 levels, PC-3 
and LSI 74 cell lines were infected with lenti-virus carrying 
pLK0.1-control shRNA and pLK0.1-HSD17B4b shRNA, 
respectively. Control shRNA and HSD 17B4b shRNA cloned 
in pLK0.1 vectors with puromycin-resistance selection 
marker were purchased from Sigma. Lentiviral stocks were 
prepared as previously described (Yu, 2012). 
Biochemistry. Western blotting: Cells were lysed in the 
appropriate volume oflysis buffer (50 mM HEPES, 100 mM 
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boiling D.D. water. Supematants were analyzed by lumi-
nescence using ATP Determination Kit (Invitrogen, 
A22066). 
Seahorse assay: 3xl04 cells were seeded in XF96 Cell 
Culture microplate (80 µL of3.75xl05 cells/m:). On the next 
day, cells were treated with DMSO or inhibitors and ana-
lyzed using the Seahorse analyzer in Redox Metabolism 
Shared Resource Facility (RM SRF) at the Markey Cancer 
NaCl, 2 mM EDTA, 1 % glycerol, 50 mM NaF, 1 mM 
Na3V04, 1% Triton X-100, with protease inhibitors). The 
following antibodies were used: HSDl 784 (GeneTex, 
GTXl 03864), AMPK (Cell Signaling, 2532), pAMPK (Cell 
Signaling, 2535), ACC (Cell Signaling, 3676), pACC (Cell 5 
Signaling, 11818), p70 (Cell Signaling, 2708), p-p70 (Cell 
Signaling, 9914), S6 (Cell Signaling, 2217), pS6 (Cell 
Signaling, 4858), MCCA (GeneTex, GTX110062), tubulin 
(Hybridoma Bank, E7), Actin (Sigma, Al 978), His-tag (BD 
Pharmingen, 552564). 10 Center. 
Streptavidin-agarose pulldown: Biotinylated compound 
15d (FIG. 2A) was incubated with cell lysates and strepta-
vidin beads. The binding proteins were pulled down and 
analyzed by 4-12% SDS-PAGE as described previously. The 
protein bands were identified by NanoLC-ESI-MS/MS at 15 
ProtTech Inc. For binding and enzymatic assays, His-tagged 
HSDl 784 constructs were clone and truncated by PCR 
using pET28. The full-length and truncated proteins were 
purified from bacteria BL21. 
The enzymatic activities of HSDl 784 were analyzed 20 
using the method reported by Novikov et al. (J. Biol. Chem., 
1994, 269, 27125). Dehydrogenase assay: The purified 
HSD 1784 enzyme was diluted in 200 µL reaction buffer ( 60 
mM Hydrazine, pH 8.0; 1 mM NAD\ 50 mM KC!; 0.01 % 
Triton-XlOO and 0.05% BSA) and incubated with 25 µM 25 
substrate, DL-~-hydroxybutyryl CoA lithium salt (Sigma 
H0261). The reaction was quantified by measuring the 
fluorescent product NADH (excitation: 340 nm; emission 
460 nm). Hydratase assay: The purified HSDl 784 enzyme 
was diluted in 200 µL reaction buffer (0.32 M Tris-HCI, 30 
pH7.4; 5.9 mM EDTA, 0.006% BSA) and incubated with 
0.2 mM substrate, crotonoyl CoA (Sigma 28007). The 
reaction was quantified by measuring the remaining sub-
strate using absorbance at 280 nm. 
Fatty acid analysis: Free and total fatty acids (after 
saponification) were prepared as reported previously (Spen-
cer et al. Diabetes 62(5):1709-1717) converted to N-(4-
aminomethylphenyl)pyridinium derivatives (Bollinger et al. 
J Lipid Res 54(12):3523-3530) and quantitated HPLC elec-
trospray ionization tandem mass spectrometry with quanti-
tation accomplished using exogenously added heptade-
canoic acid as a recovery standard and reference to offline 
calibrations generated using authentic fatty acid standards. 
Compound 
lOa 
!Ob 
lOc 
lOd 
lOe 
!Of 
lOg 
!Oh 
lOi 
lOj 
!Ok 
101 
!Om 
!On 
lOo 
!Op 
lOq 
!Or 
!Os 
Cell Metabolism. Acetyl-CoA analysis: Cells grown in 6 
cm plates were treated with DMSO or inhibitors, and 
harvested in lysis buffer (20 mM Tris pH 7 .5, 150 mM NaCl, 
1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM 
sodium pyrophosphate, 1 mM Na3 V04 , 1 ug/mL Leupeptin, 
1 mM PMSF and 1: 100 Protease inhibitor cocktail). Super-
natants were analyzed using PicoProbe Acetyl CoA kit 
(Abeam, ab87546). 
ATP analysis: Cells growing in 12-well plates were 
treated with DMSO or inhibitors, and lysed by adding 1 mL 
The following cytisine-linked isoflavonoid compounds 
were tested for AMPK activation. 
(III) 
8 
CY-CH2-Z-CH2(CH2)nOw: I O 1' R 
3 Ar 
5 
0 
AMPK-fold 
Ar R n z CY Activation (10 µM) 
C6H4 -4-Cl H 0 CH2 12-cytisinyl 3.6 
C6H4 -4-Cl CH3 0 CH2 12-cytisinyl 9.9 
C6H4 -4-Cl CH3 1 CH2 12-cytisinyl 4.1 
C6H4 -4-Cl H 1 CH(OH) 12-cytisinyl 2.2 
C6H4 -4-Cl CH3 1 CH(OH) 12-cytisinyl 1.3 
C6H4 -4-Cl CH3 1 C=O 12-cytisinyl NIA 
C6H4 -4-Cl CH3 2 CH(OH) 12-cytisinyl 3.2 
C6H4 -4-Cl CH3 3 CH(OH) 12-cytisinyl 2.9 
C6H4 -4-Cl CH3 3 C=O 12-cytisinyl NIA 
C6H4 -4-Cl CH3 4 CH(OH) 12-cytisinyl 3.2 
C6H4 -4-Cl CH3 4 C=O 12-cytisinyl 1.1 (at 3 µM) 
C6Hs H 0 CH2 12-cytisinyl 2 
C6Hs CH3 0 CH2 12-cytisinyl 3.4 
C6H4 -4-Br H 0 CH2 12-cytisinyl 8.4 
C6H4 -4-Br CH3 0 CH2 12-cytisinyl 5.9 
C6H4 -4-0Me H 0 CH2 12-cytisinyl 
C6H4 -4-0Me CH3 0 CH2 12-cytisinyl 4.2 
C6H3-3,4-(0Me)o H 0 CH2 12-cytisinyl 2.4 
C6H3-3,4-(0Me)o CH3 0 CH2 12-cytisinyl 4.9 
Preparation of Cytisine-Linked Isoflavonoids. 
Materials and Characterization. Chemicals were pur-
chased from Sigma Aldrich (Milwaukee, Wis.) or Fisher 
60 Scientific (Pittsburgh, Pa.) or were synthesized according to 
literature procedures. Hydrazide-PEG4 -biotin was pur-
chased from Thermo Fisher Scientific (Florence, Ky.). Sol-
vents were used from commercial vendors without further 
purification unless otherwise noted. Nuclear magnetic reso-
65 nance spectra were determined on a Varian instrument (lH, 
400 MHz; 13C, 100 Mz). High resolution mass spectra 
(HRMS) were recorded on a Thermo Scientific Q Exactive 
US 10,188,743 B2 
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Orbitrap mass spectrometer. Resolution was set at 140,000. 
Samples were introduced through direct infusion using a 
syringe pump with a flow rate of 5 µUmin. Purity of 
compounds was greater than 95% as established using 
combustion analyses determined by Atlantic Microlabs, Inc. 5 
(Norcross, Ga.). Compounds were chromatographed on pre-
parative layer Merck silica gel F254 unless otherwise indi-
cated. 
lH, J=8.6, 2 Hz), 6.83 (d, lH, J=2 Hz), 2.24 (s, 3H); 13C 
NMR (100 MHz, DMSO-d6 ) ll 174.6, 162.8, 162.6, 157.1, 
132.5, 132.3, 132.2, 128.1, 127.1, 121, 115.4, 114.9, 101.9, 
19.2. HRMS (ESI) Calcd for C16H120 3Cl: 287.0480 
(M+Ht. Found 287.0471. Anal. Calcd for C16Hu03 Cl: C, 
67.03; H, 3.87. Found: C, 66.87; H, 4.04. 
General Procedure of for the Synthesis Deoxybenzoins 5. 
To a mixture of resorcinol (60 mmol) and phenylacetic 
acid (60 mmol) under an argon atmosphere was added 74 General Procedure for the Synthesis of Isoflavones 3. 
To a solution of deoxybenzoin (10 mmol) in DMF (7 mL) 
at 30-40° C. under an argon atmosphere was added dropwise 
3.7 mL of a 98% solution of boron trifluoride etherate. The 
mixture was stirred for 30 min, and phosphorous oxytrichlo-
ride (2 mL, 21.5 mmol) was added. The mixture was heated 
at 60° C. for 3-5 h, cooled, poured into water and extracted 
with ethyl acetate. The organic solution was dried over 
anhydrous MgS04 . The product was isolated by crystalli-
zation (from either methanol or ethanol) to afford isofla-
vones 3. 
7-Hydroxy-3-phenyl-4H-chromen-4-one (3a) 
Yield: 69%; mp 209-210° C. (lit1 mp 210-213° C.). 1H 
NMR (400 MHz, DMSO-d6 ) Ii 10.86 (s, lH), 8.41 (s, lH), 
8 (d, lH, J=8.8 Hz), 7.62-7.55 (m, 2H), 7.5-7.36 (m, 3H), 
6.97 (dd, lH, J=8.8, 2 Hz), 6.9 (d, lH, J=2 Hz); 13C NMR 
(100 MHz, DMSO-d6) ll 174.4, 162.7, 157.5, 153.9, 132.1, 
129, 128.1, 127.7, 127.3, 123.6, 116.6, 115.3, 102.2. NMR 
data was consistent with reported data. 
7 -Hydroxy-3-( 4-methoxypheny 1)-4 H-chromen-4-one 
(3b) 
Yield: 53%; mp 259-260° C. (lit9 mp 259-261 ° C.). 1H 
NMR (400 MHz, DMSO-d6 ) ll 10.8 (s, lH), 8.34 (lH), 7.97 
10 mL of 98% solution of boron trifluoride etherate. The 
mixture was heated to 85° C. for 3-5 h. The mixture was 
poured into cold water and extracted with ethyl acetate. The 
combined organic layers were washed with brine and dried 
15 
over anhydrous MgS04 . The product was purified by col-
unm chromatography (using 1 :20 to 1 :3 ethyl acetate-
hexanes or using 1:99 to 2:98 methanol-dichloromethane) to 
afford deoxybenzoins 5. 
20 
1-(2,4-dihydroxyphenyl)-2-phenylethanone (5a) 
Yield: 60%; mp 111-112° C. (lit4 mp 110-113° C.); 1H 
NMR (400 MHz, CDCl3 ) ll 12.69 (s, lH), 7.75 (d, lH, J=8.6 
Hz), 7.37-7.32 (m, 2H), 7.3-7.24 (m, 3H), 6.4-6.34 (m, 2H), 
5.76 (s, lH), 4.21 (s, 2H); 13C NMR (100 MHz, CDCl3 ) Ii 
25 202.4, 165.7, 162.9, 134.4, 133, 129.5, 128.9, 127.3, 113.7, 
108.2, 103.8, 45. NMR data was consistent with reported 
data in DMSO-d6 . 
30 
1-(2,4-Dihydroxyphenyl)-2-( 4-methoxyphenyl)etha-
none (5b) 
Yield: 63%; mp 154-155° C. (lit4 mp 156-157° C.); 1H 
NMR (400 MHz, DMSO-d6 ) ll 12.56 (s, lH), 10.66 (s, lH), 
7.94 (d, lH, J=9 Hz), 7.2 (d, 2H, J=8.8 Hz), 6.87 (d, 2H, 
35 J=8.8 Hz), 6.39 (dd, lH, J=9, 2.3 Hz), 6.25 (d, lH, J=2.3 
Hz), 4.2 (s, 2H), 3.72 (s, 3H); 13C NMR (100 MHz, 
DMSO-d6 ) Ii 202.5, 164.9, 164.7, 158, 133.6, 130.5, 127, 
113.8, 112.1, 108.2, 102.5, 55, 43.2. NMR data was consis-
tent with reported data in DMSO-d6 . 
(d, lH, J=8.7), 7.51 (d, 2H, J=8.8 Hz), 6.99 (d, 2H, J=8.8 
Hz), 6.94 (dd, lH, J=8.7, 2.3 Hz), 6.87 (d, lH, J=2.3 Hz), 
3.78 (s, 3H); 13C NMR (100 MHz, DMSO-d6) Ii 174.6, 
162.6, 158.9, 157.4, 153.2, 130.1, 127.3, 124.2, 123.2, 
116.6, 115.2, 113.6, 102.1, 55.2. NMR data was consistent 40 
with reported data. a-4-Chlorophenyl-2,4-dihydroxyacetophenone (Sc) 
3-( 4-Chlorophenyl)-7-hydroxy-4H-chromen-4-one 
(3c) 
Yield: 59%; mp 260-261 ° C. (lit14 mp 260° C.); 1H NMR 
(400MHz, DMSO-d6 ) ll 10.86 (s, lH), 8.45 (s, lH), 7.98 (d, 
lH, J=8.8 Hz), 7.61 (d, 2H, J=8.4 Hz), 7.5 (d, 2H, J=8.4 Hz), 
6.96 (dd, lH, J=8.8, 2.4 Hz), 6.89 (d, lH, 1=2.4 Hz); 13C 
NMR (100 MHz, DMSO-d6) ll 174.2, 162.8, 157.5, 154.1, 
132.5, 131, 130.7, 128.1, 127.3, 122.3, 116.5, 115.4, 102.2. 
NMR data was consistent with reported data. 
3-( 4-Chlorophenyl)-7-hydroxy-2-methyl-4H-
chromen-4-one (3d) 
Acetic anhydride (3 mL, 31.7 mmol) was added to a 
suspension of potassium carbonate (94.2 g, 30.4 mmol) and 
a-4-chlorophenyl-2,4-dihydroxyacetophenone (2 g, 7.6 
mmol) in DMF (20 mL) and the resulting suspension was 
heated at 120° C. for 8 h under an argon atmosphere. The 
mixture was cooled and poured into water (100 mL). The 
precipitate was filtered, washed with water (two 100 mL 
portions) and diethyl ether (100 mL) to afford 1.91 g (88%) 
Yield: 49%; mp 157-158° C. (lit4 mp 150-150.5° C.); 1H 
NMR (400 MHz, DMSO-d6 ) ll 12.41 (s, lH), 10.71 (s, lH), 
45 7.93 (d, lH, J=9 Hz), 7.37 (d, 2H, J=8.2 Hz), 7.29 (d, 2H, 
J=8.2 Hz), 6.41 (dd, lH, J=9, 1.6 Hz), 6.26 (d, lH, J=l.6 
Hz), 4.33 (s, 2H); 13C NMR (100 MHz, DMSO-d6 ) Ii 201.6, 
165, 164.5, 134.2, 133.5, 131.6, 131.4, 128.3, 112.3, 108.3, 
102.5, 43.4. NMR data was consistent with reported data in 
50 acetone-d65 and methanol-d46 . 
55 
General Procedure for 
7-(2-bromoethoxy )isoflavones 6 
To a solution of 2 mmol of7-hydroxyisoflavone 3 in DMF 
(10 mL) was added K 2 C03 (690 mg, 5 mmol) and 1,2-
dibromoethane (0.9 mL, 10.4 mmol). The mixture was 
stirred for 3 h at 80° C. under a nitrogen atmosphere. The 
product was cooled and poured into cold water. The pre-
60 cipitate was filtered, washed successively with water and 
cold diethyl ether to afford 7-(2-bromoethoxy)isoflavones 6. 
7-(2-Bromoethoxy )-3-phenyl-4H-chromen-4-one 
(6a) 
of the product as a white solid: mp 277-278° C.; 1H NMR 65 
(400 MHz, DMSO-d6) ll 10.88 (s, lH), 7.87 (d, lH, J=8.6 
Hz), 7.48 (d, 2H, J=8.4 Hz), 7.3 (d, 2H, J=8.4 Hz), 6.9 (dd, 
Yield: 77%; mp 200-201 ° C. (lit13 mp 202-204° C.); 1H 
NMR (400 MHz, CDCl3 ) Ii 8.24 (d, lH, J=8.8 Hz), 7.95 (s, 
US 10,188,743 B2 
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lH), 7.56 (d, 2H, 1=7.2 Hz), 7.48-7.34 (m, 3H), 7.02 (dd, 
lH, 1=8.8, 2 Hz), 6.88 (d, lH, 1=2 Hz), 4.4 (t, 2H, 1=6.l Hz), 
3.7 (t, lH, 1=6.l Hz); 13C NMR (100 MHz, CDC13 ) ll 175.7, 
162.5, 157.9, 152.8, 132, 129.1, 128.6, 128.3 (128.31), 
128.3 (128.27), 125.5, 119.1, 114.8, 101.3, 68.3, 28.4. NMR 5 
data was consistent with reported data in DMSO-d6 . 
7-(2-Bromoethoxy )-3-( 4-methoxyphenyl)-4H-
chromen-4-one ( 6b) 
16 
and the product was purified by colunm chromatography 
using methanol-dichloromethane (1:9 to 1:3) to afford pip-
erazinyl-substituted isoflavones 7 or 8 as white solids. 
3-( 4-Chlorophenyl)-7-(2-(piperazin-1-yl)ethoxy)-
4H-chromen-4-one (7c) 
To a solution of378 mg (1 mmole) of 6c in DMF (10 mL) 
was added piperazine (172 mg, 2 mmol), Nal (150 mg, 1 
Yield: 80%. mp 174-175° C. (lit12 mp 181.5-182.5° C.); 
1H NMR (400 MHz, DMSO-d6) ll 8.44 (s, lH), 8.05 (d, lH, 
1=8.8 Hz), 7.53 (d, 2H, 1=8.6 Hz), 7.22 (d, lH, 1=2.4 Hz), 
7.12 (dd, lH, 1=8.8, 2.4 Hz), 7 (d, 2H, 1=8.6 Hz), 4.5 (t, 2H, 
1=5.2 Hz), 3.87 (t, 2H, 1=5.2 Hz), 3.79 (s, 3H); 1H NMR 
(400 MHz, CDC13 ) ll 8.23 (d, lH, 1=9 Hz), 7.93 (s, lH), 7.5 
(d, 2H, 1=8.8 Hz), 7.01 (dd, lH, 1=9, 2.4 Hz), 6.97 (d, 2H, 
1=8.8 Hz), 6.86 (d, lH, 1=2.4 Hz), 4.4 (t, 2H, 1=6.4 Hz), 3.84 
(s, 3H), 3.7 (t, 2H, 1=6.4 Hz); 13C NMR (100 MHz, CDC13 ) 
Ii 175.9, 162.4, 159.7, 157.9, 152.2, 130.2, 128.2, 125.1, 
124.2, 119, 114.7, 114.1, 101.2, 68.3, 55.5, 28.5. NMR data 
was consistent with reported data in CDC13 . 
10 mmol). and K2C03 (276 mg, 2 mmol). The mixture was 
stirred for 2 h at 60° C. under a nitrogen atmosphere. The 
mixture was cooled and poured into cold water (100 mL). 
The precipitated was collected and washed with cold water. 
The product was recrystallized from methanol to afford 306 
15 mg (79%) of7c as a white solid: mp 147-148° C.; 1H NMR 
(400 MHz, CDC13 ) 8.19 (d, lH, 1=9 Hz), 7.94 (s, lH), 7.5 
(d, 2H, 1=8.6 Hz), 7.4 (d, 2H, 1=8.6 Hz), 7 (dd, lH, 1=9, 2.4 
Hz), 6.86 (d, lH, 1=2.4 Hz), 4.2 (t, 2H, 1=5.7 Hz), 2.96-2.9 
(m, 4H), 2.87 (t, 2H, 1=5.7 Hz), 2.64-2.53 (m, 4H); 13C 
7-(2-Bromoethyloxy )-3-( 4-chlorophenyl)chromen-4-
one (6c) 
20 NMR (100 MHz, CDC13 ) ll 175.5, 163.4, 158, 152.7, 134.3, 
130.5, 130.4, 128.8, 127.9, 124.4, 118.5, 115.2, 101, 66.7, 
57.6, 54.9, 46.1. HRMS (ESI) Calcd for C21 H220 3 N2Cl: 
385.1324 (M+H)+. Found 385.1327. Rapid air oxidation 
precluded obtaining a satisfactory combustion analysis. 
25 
Yield: 85%; mp 188-189° C.; 1H NMR (400 MHz, 
DMSO-d6 ) ll 8.54 (s, lH), 8.06 (d, lH, 1=9 Hz), 7.64 (d, 2H, 
1=8.4 Hz), 7.51 (d, 2H, 1=8.4 Hz), 7.25 (d, lH, 1=2.4 Hz), 
7.14 (dd, lH, 1=9; 2.4 Hz), 4.51 (t, 2H, 1=5.3 Hz), 3.87 (t, 30 
2H, 1=5.3 Hz); 1H NMR (400 MHz, CDC13 ) Ii 8.23 (d, lH, 
1=9.2 Hz), 7.95 (s, lH), 7.51 (d, 2H, 1=8.4 Hz), 7.41 (d, 2H, 
1=8.4 Hz), 7.03 (dd, lH, 1=9.2, 2.4 Hz), 6.88 (d, lH, 1=2.4 
Hz), 4.4 (t, 2H, 1=6.3 Hz), 3.7 (t, 2H, 1=6.3 Hz); 13C NMR 
(100 MHz, CDC13 ) Ii 175.4, 162.6, 157.9, 152.8, 134.3, 35 
130.4, 130.3, 128.8, 128.2, 124.5, 118.9, 114.9, 101.3, 68.4, 
28.4. HRMS (ESI) Calcd for C17H130 3 Br3
7Cl: 380.9713 
(M+Ht. Found: 380.9711. Anal. Calcd for C17H120 3 BrCl: 
C, 53.79; H, 3.19. Found: C, 54.09; H, 3.27. 
7-(2-( 4-(2-Hydroxyethyl)piperazin-1-yl)ethoxy)-3-
phenyl-4H-chromen-4-one (Sa) 
Yield: 60%; mp 159-160° C.; 1H NMR (400 MHz, 
CDC13 ) ll 8.21 (d, lH, 1=8.8 Hz), 7.95 (s, lH), 7.6-7.52 (m, 
2H), 7.48-7.34 (m, 3H), 7 (dd, lH, 1=8.8, 2 Hz), 6.87 (d, lH, 
1=2 Hz), 4.21 (t, 2H, 1=5.6 Hz), 3.65 (t, 2H, 1=5.6 Hz), 2.89 
(t, 2H, 1=5.6 Hz), 2.78-2.52 (m, SH), 2.6 (t, 2H, 1=5.6 Hz); 
13C NMR (100 MHz, DMSO-d6) ll 174.4, 163, 157.5, 154.2, 
132, 128.9, 128.1, 127.8, 126.9, 123.8, 117.6, 115.2, 101.2, 
66.5, 60.2, 58.4, 56.4, 53.2, 53; 13C NMR (100 MHz, 
CDC13 ) Ii 175.7, 163.2, 158, 152.8, 132.1, 129.1, 128.6, 
128.3, 128, 125.5, 118.7, 115, 101, 66.8, 59.4, 57.8, 56.9, 
53.7, 52.9. HRMS (ESI) Calcd for C23H270 4 N2 : 395.1965 
7-(2-Bromoethoxy )-3-( 4-chlorophenyl)-2-methyl-
4H-chromen-4-one (6d) 
40 (M+H)*. Found 395.1957. Anal. Calcd. for C23H26N20 4 : C, 
70.03; H, 6.64; N, 7.10. Found: C, 69.79; H, 6.65; N, 7.07. 
To a solution of 7-hydroxyisoflavone 3d (573 mg, 2 
mmol) in anhydrous DMF (10 mL) was added K2 C03 (690 45 
mg, 5 mmol) and 1,2-dibromoethane (0.9 mL, 10.4 mmol). 
The mixture was stirred at 80° C. for 3 h under a nitrogen 
atmosphere. The mixture was filtered, and DMF was evapo-
rated. The product was isolated by colunm chromatography 
using ethyl acetate-hexanes (from 1 :9 to 3:7) to give 485 mg 50 
(62%) of 6d: mp 160-161 ° C. (lit12 mp 165-167° C.); 1H 
NMR (400 MHz, DMSO-d6) Ii 7.95 (d, lH, 1=8.6 Hz), 7.5 
(d, 2H, 1=8.4 Hz), 7.33 (d, 2H, 1=8.4 Hz), 7.21 (d, lH, 1=2.4 
Hz), 7.09 (dd, lH, 1=8.6; 2.4 Hz), 4.5 (t, 2H, 1=5.5 Hz), 3.87 
(t, 2H, 1=5.5 Hz), 2.27 (s, 3H); 13C NMR (100 MHz, 55 
DMSO-d6 ) Ii 174.6, 163.2, 162.3, 157, 132.5, 132.3, 132, 
128.1, 126.9, 121.3, 116.7, 114.8, 101.2, 68.5, 31, 19.2. 
NMR data was consistent with reported data in CDC1312 . 
Anal. Calcd for C18H140 3BrCl: C, 54.92; H, 3.58. Found: C, 
54.85; H, 3.48. 60 
General Procedure for the Synthesis of Piperazinyl Iso-
flavones 7 and 8. 
A mixture of 1 mmole of isoflavone 6, either piperazine 
or 1-(2-hydroxyethyl)piperazine (1.2 mmol), Nal (1 mmol) 
and diisopropylethylamine (0.6 mL, 3.5 mmol) in DMF (9 65 
mL) was stirred for 3 h at 60° C. under a nitrogen atmo-
sphere. The mixture was cooled; the solvent was evaporated; 
7-[2-[ 4-(2-Hydroxyethyl)piperazin-1-yl]ethoxy ]-3-
( 4-methoxyphenyl) chromen-4-one (Sb) 
Yield: 73%; mp 145-146° C.; 1H NMR (400 MHz, 
CDC13 ) Ii 8.2 (d, lH, 1=8.8 Hz), 7.92 (s, lH), 7.5 (d, 2H, 
1=9.2 Hz), 7 (dd, lH, 1=8.8, 2.4 Hz), 6.97 (d, 2H, 1=9.2 Hz), 
6.86 (d, lH, 1=2.4 Hz), 4.2 (t, 2H, 1=5.8 Hz), 3.84 (s, 3H), 
3.63 (t, 2H, 1=5.2 Hz), 2.88 (t, 2H, 1=5.8 Hz), 2.74-2.54 (m, 
SH), 2.57 (t, 2H, 1=5.2 Hz); 13C NMR (100 MHz, CDC13 ) 
Ii 176, 163.1, 159.7, 158, 152.2, 130.2, 127.9, 125, 124.3, 
118.6, 114.9, 114.1, 100.9, 66.7, 59.5, 57.7, 56.9, 55.5, 53.5, 
52.9. HRMS (ESI) Calcd for C24H290 5 N2 : 425.2071 
(M+Ht. Found 425.2071. Anal. Calcd. for C24H28N2 0 5 : C, 
67.91; H, 6.65; N, 6.60. Found: C, 68.15; H, 6.71; N, 6.56. 
3-( 4-Chlorophenyl)-7-(2-( 4-(2-hydroxyethyl)piper-
azin-1-yl)ethoxy)-4H-chromen-one (Sc) 
Yield: 74%; mp 152-153° C.; 1H NMR (400 MHz, 
CDC13 ) Ii 8.2 (d, lH, 1=8.8 Hz), 7.94 (s, lH), 7.51 (d, 2H, 
1=8.2 Hz), 7.41 (d, 2H, 1=8.2 Hz), 7.02 (dd, lH, 1=8.8, 2.4 
Hz), 6.87 (d, lH, 1=2.4 Hz), 4.21 (t, 2H, 1=5.6 Hz), 3.62 (t, 
2H, 1=5.2 Hz), 2.88 (t, 2H, 1=5.6 Hz), 2.72-2.5 (m, SH), 2.57 
(t, 2H, 1=5.2 Hz); 13C NMR (100 MHz, CDC13 ) Ii 175.5, 
163.4, 158, 152.7, 134.3, 130.5, 130.4, 128.8, 127.9, 124.4, 
US 10,188,743 B2 
17 
118.5, 115.2, 101, 66.8, 59.3, 57.8, 56.9, 53.8, 52.9. HRMS 
(ESI) Calcd for C23H260 4 N2Cl: 429.1576 (M+Ht. Found 
429.1577. Anal. Calcd. for C23H25N20 4 Cl: C, 64.41; H, 
5.88; N, 6.53. Found: C, 64.52; H, 6.01; N, 6.50. 
General Procedure for the Synthesis of Cytisinyl-Linked 5 
Isoflavones 10. 
Amixture of0.5 mmol of7-(2-bromoethoxy)isoflavone 6, 
cytisine (143 mg, 0.75 mmol), Nal (75 mg, 0.5 mmol), and 
diisopropylethylamine (0.3 mL, 3.5 mmol) in DMF (5 mL) 
was stirred for 2-4 hat 80° C. under a nitrogen atmosphere. 10 
The mixture was cooled and poured into cold water. A 
precipitate was collected and purified by column chroma-
tography using methanol-dichloromethane (2:98 to 5:95) to 
afford cytisinyl-linked isoflavones 10 as white solids. 
18 
C25H260 4 N2C: 489.1576 (M+Ht. Found: 489.1577. Anal. 
Calcd. for C28H25CIN20 4 : C, 68.78; H, 5.15; N, 5.73. 
Found: C, 69.02; H, 5.41; N, 5.63. 
(1 R,5 S )-3-(2-( (3-( 4-Chloropheny 1)-2-methy 1-4-oxo-
4 H-chromen-7-yl)oxy)ethyl)-3,4,5,6-tetrahydro- l H-
1,5-methanopyrido[ 1,2-a] [1,5]diazocin-8(2H)-one 
(lOd) 
Yield: 62%; mp 186-187° C.; 1H NMR (400 MHz, 
methanol-d4 ) Ii 7.96 (d, lH, 1=8.4 Hz), 7.45 (d, 2H, 1=8.6 
Hz), 7.39 (dd, lH, 1=8.9, 6.9 Hz), 7.28 (d, 2H, 1=8.6 Hz), 
6.94-6.9 (m, lH), 6.89 (d, lH, 1=2 Hz), 6.35 (dd, lH, 1=8.9, 
1.2 Hz), 6.25 (dd, lH, 1=6.9, 1.2 Hz), 4.12-4.04 (m, 2H), 4 
(1 R,5S)-3-(2-( ( 4-0xo-3-phenyl-4H-chromen-7-yl) 
oxy)ethyl)-3,4,5,6-tetrahydro- l H-1,5-methanopyrido 
[1,2-a ][1,5]diazocin-8(2H)-one (1 Oa) 
15 (d, lH, 1=15.4 Hz), 3.88 (dd, lH, 1=15.4, 6.4 Hz), 3.13-2.98 
(m, 3H), 2.78-2.72 (m, 2H), 2.6-2.44 (m, 3H), 2.3 (s, 3H), 
1.96-1.82 (m, 2H); 13C NMR (100 MHz, methanol-d4 ) Ii 
178, 165.8, 165.5, 165.1, 159.2, 153.8, 141.2, 134.9, 133.6, 
133.2, 129.6, 128, 123.2, 117.8, 116.4, 116.2, 107.7, 101.9, 
20 67.8, 61.9, 61.4, 57.3, 51.6, 36.9, 29.5, 26.3, 19.6. HRMS 
(ESI) Calcd for C29H28ClN20 4 : 503.1732 (M+Ht. Found: 
503.1735. Anal. Calcd. for C29H270 4 N2Cl: C, 69.25; H, 
5.41; N, 5.57. Found: C, 68.98; H, 5.36; N, 5.50. 
Yield: 72%; mp 197-198° C. (lit13 mp 195-196° C.); 1H 
NMR (400 MHz, DMSO-d6) ll 8.46 (s, lH), 7.99 (d, lH, 1=9 
Hz), 7.62-7.55 (m, 2H), 7.48-7.34 (m, 3H), 7.29 (dd, lH, 
1=8.9, 6.7 Hz), 7.11 (d, lH, 1=2.4 Hz), 6.98 (dd, lH, 1=9, 2.4 
Hz), 6.18 (dd, lH, 1=8.9, 1.2 Hz), 6.07 (dd, lH, 1=6.7, 1.2 
Hz), 4.2-4.04 (m, 2H), 3.82-3.64 (m, 2H), 3.06-2.98 (m, 25 
2H), 2.94-2.86 (m, lH), 2.76-2.62 (m, 2H), 2.52-2.34 (m, 
3H), 1.79 (d, lH, 1=12.5 Hz), 1.7 (d, lH, 1=12.5 Hz); 13C 
NMR (100 MHz, DMSO-d6) ll 174.4, 162.9, 162.2, 157.4, 
154.2, 152.1, 138.7, 132, 128.9, 128.2, 127.8, 126.9, 123.7, 
117.6, 115.3, 115.1, 103.7, 101.3, 66.3, 60.3, 59.4, 55.7. 30 
49.5, 34.6, 27.3, 25. NMR data was consistent with reported 
data in DMSO-d6. 
3-( 4-Chlorophenyl)-7-(hex-5-en-1-yloxy)-2-methyl-
4H-chromen-4-one (lld) 
To a solution of 7-hydroxyflavone 3d (573 mg, 2 mmol) 
in DMF (10 mL) was added K2C03 (690 mg, 5 mmol) and 
6-bromo-1-hexene (0.6 mL, 4.5 mmol). The mixture was 
stirred at 80° C. for 1 h under a nitrogen atmosphere. The 
mixture was cooled, diluted with water, and extracted with 
ethyl acetate. The combined organic layers were washed 
successively with water and brine and dried over anhydrous (1R,5S)-3-(2-((3-( 4-Methoxyphenyl)-4-oxo-4H-
chromen-7-yl)oxy )ethyl)-3,4,5,6-tetrahydro- lH-1,5-
methanopyrido[l ,2-a] [1,5]diazocin-8(2H)-one (1 Ob) 
35 MgS04 . The product was isolated by colunm chromatogra-
phy using ethyl acetate-hexanes as eluent (from 5:95 to 1:5) 
to afford 600 mg (81 % ) of 11 d as a white solid: mp 104 ° C.; 
1H NMR (400 MHz, DMSO-d6) Ii 7.93 (d, lH, 1=8.6 Hz), 
7.49 (d, 2H, 1=8.4 Hz), 7.32 (d, 2H, 1=8.4 Hz), 7.14 (d, lH, 
Yield: 76%; mp 117-118° C. (lit13 mp 85-86° C.); 1H 
NMR(400MHz,DMSO-d6)8.41 (s, lH), 7.98(d, lH,1=8.8 
Hz), 7.52 (d, 2H, 1=8.8 Hz), 7.29 (dd, lH, 1=8.9, 6.9 Hz), 
7.09 (d, lH, 1=2 Hz), 7.04-6.92 (m, 3H), 6.18 (dd, lH, 1=8.9, 
0.8 Hz), 6.06 (d, lH, 1=6.9 Hz), 4.18-4.04 (m, 2H), 3.82-
3.66 (m, 2H), 3.79 (s, 3H), 3.06-2.98 (m, 2H), 2.94-2.86 (m, 
lH), 2.76-2.62 (m, 2H), 2.52-2.32 (m, 3H), 1.84-1.66 (m, 
2H); 13C NMR (100 MHz, CDC13 ) Ii 175.9, 163.7, 162.9, 
159.6, 157.9, 152.2, 151.4, 138.7, 130.2, 127.8, 124.8, 
124.3, 118.5, 116.7, 114.8, 114, 104.6, 100.8, 66.7, 60.9, 
60.4, 56.2, 55.4, 50, 35.6, 28.1, 25.7. NMR data was 
consistent with reported data in DMSO-d6
13
. HRMS (ESI) 
Calcd for C29H290 5N2: 485.2071 (M+Ht. Found: 50 
485.2071. Anal. Calcd. for C29H25N20 5: C, 71.88; H, 5.82; 
40 1=2.3 Hz), 7.04 (dd, lH, 1=8.6; 2.3 Hz), 5.9-5.76 (m, lH), 
5.08-4.95 (m, 2H), 4.13 (t, 2H, 1=6.4 Hz), 2.27 (s, 3H), 
2.14-2.07 (m, 2H), 1.82-1.72 (m, 2H), 1.58-1.48 (m, 2H); 
13C NMR (100 MHz, DMSO-d6) ll 174.6, 163.1 (163.13), 
163.1 (163.11), 157.1, 138.5, 132.5, 132.3, 132.1, 128.1, 
45 126.8, 121.3, 116.3, 115, 114.9, 100.8, 68.3, 32.8, 27.9, 24.6, 
19.2. HRMS (ESI) m/z Calcd for C22H220 3Cl: 369.1263 
(M+Ht. Found: 369.1253. Anal. Calcd. for C22H220 3 Cl: C, 
71.64; H, 5.74. Found: C, 71.55; H, 5.59. 
3-( 4-Chlorophenyl)-2-methyl-7-( 4-( oxiran-2-yl)bu-
toxy )-4H-chromen-4-one (12d) 
N, 5.78. Found: C, 71.60; H, 5.75; N, 5.73. 
(1 S,5S)-3-(2-((3-( 4-chlorophenyl)-4-oxo-4H-
chromen-7-yl)oxy )ethyl)-3,4,5,6-tetrahydro- lH-1,5-
methanopyrido[l ,2-a] [1,5]diazocin-8(2H)-one (1 Oc) 
Yield: 76%; mp 146-147° C.; 1H NMR (400 MHz, 
CDC13 ) Ii 8.16 (d, lH, 1=8.8 Hz), 7.94 (s, lH), 7.51 (d, 2H, 
1=8.6 Hz), 7.4 (d, 2H, 1=8.6 Hz), 7.3-7.18 (m, lH), 6.9 (dd, 
lH, 1=8.8, 2 Hz), 6.76 (d, lH, 1=2 Hz), 6.43 (d, lH, 1=8.8 
Hz), 5.96 (d, lH, 1=6.8 Hz), 4.14-3.86 (m, 4H), 3.08-2.92 
(m, 3H), 2.75 (t, 2H, 1=5.6 Hz), 2.6-2.42 (m, 3H), 1.94-1.76 
(m, 2H); 13C NMR (100 MHz, CDC13 ) Ii 175.5, 163.7, 
163.1, 158, 152.7, 151.4, 138.8, 134.2, 130.5, 130.3, 128.8, 
127.9, 124.3, 118.4, 116.8, 115.1, 104.7, 100.9, 66.8, 61, 
60.5, 56.2, 50.1, 35.6, 28.1, 25.8. HRMS (ESI) Calcd for 
A solution of 77% meta-chloroperoxybenzoic acid (896 
mg, 4 mmol) in dichloromethane (5 mL) was added to a 
55 solution of 1 ld (338 mg, 0.92 mmol) in dichloromethane (5 
mL). The mixture was stirred for 4 h at 25° C. under a 
nitrogen atmosphere. The product was poured into saturated 
NaHC03 solution and extracted with dichloromethane. The 
organic layers were washed with brine and dried over 
60 anhydrous MgS04 . The product was purified by column 
chromatography using methanol-dichloromethane (ratio 
ranging from 2:98 to 2:48) to afford 234 mg (76%) of 12d: 
mp 118-119° C.; 1HNMR(400MHz, CDC13 ) ll 8.11 (d, lH, 
1=8.8 Hz), 7.4 (d, 2H, 1=8.4 Hz), 7.23 (d, 2H, 1=8.4 Hz), 
65 6.95 (dd, lH, 1=8.8, 2.4 Hz), 6.82 (d, lH, 1=2.4 Hz), 4.08 (t, 
2H, 1=6.2 Hz), 3-2.92 (m, lH), 2.79 (t, lH, 1=4.4 Hz), 
2.54-2.48 (m, lH), 2.29 (s, 3H), 1.96-1.86 (m, 2H), 1.76-
US 10,188,743 B2 
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1.54 (m, 4H); 13C NMR (100 MHz, CDC13 ) ll 176.1, 163.5, 
162.8, 157.7, 133.8, 132, 131.8, 128.7, 127.7, 122.4, 117.2, 
114.7, 100.5, 68.4, 52.2, 47.1, 32.3, 28.9, 22.8, 19.5. HRMS 
(ESI) Calcd for C22H2 0 4 Cl: 385.1201 (M+Ht. Found: 
385.1212. Anal. Calcd. for C22H21 Cl04 : C, 68.66; H, 5.50. 5 
Found: C, 68.39; H, 5.50. 
20 
N-(22-( (3-( 4-chlorophenyl)-2-methyl-4-oxo-4H-
chromen-7-yl)oxy)-15-oxo-18-(((1 S,5S)-8-oxo- l ,5, 
6,8-tetrahydro-2H-1,5-methanopyrido[ 1,2-a] [,5]di-
azocin-3( 4H)-yl)methyl)-3,6,9, 12-tetraoxa-16,17-
diazadocos-l 7-en-1-yl)-5-(( 4S)-2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-yl)pentanamide (15d) 
A mixture of hydrazide-PEG4 -biotin (Thermo Fisher, 50 
mg, 0.1 mmol), 14d (57 mg, 0.1 mmol), and cerium trichlo-
( 1 S,5 S )-3-( 6-( (3-( 4-Chloropheny 1)-2-methy 1-4-oxo-
4 H-chromen-7-yl)oxy)-2-hydroxyhexyl)-3,4,5,6-
tetrahydro- l H-1,5-methanopyrido[ 1,2-a] [ 1,5]diazo-
cin-8(2H)-one (13d) 
10 ride (3 mg, 0.01 mmol) in methanol (3 mL) was stirred at 
60° C. for 4 h. The solvent was evaporated, and the product 
was isolated by preparative chromatography using metha-
nol-dichloromethane (8:92) to afford 25 mg (24%) of 15d as 
a mixture of syn/anti-isomers: 1H NMR (400 MHz, CDC13 ) 
A mixture of 12d (327 mg, 0.8 mmol) and cytisine (194 
mg, 1 mmol) in absolute ethanol (9 mL) was stirred in a 
pressure tube for 20 h at 90° C. The solvent was evaporated, 
and the product was purified by colunm chromatography 
using methanol-dichloromethane (2:48) to afford 470 mg 
(96%) of 13d as a mixture of diastereoisomers: 1H NMR 
(400 MHz, CDC13 ) Ii 8.08 and 8.07 (two d, lH, 1=9.2 Hz), 
7.39 (d, 2H, 1=8.4 Hz), 7.32-7.16 (m, 3H), 6.96-6.86 (m, 
lH), 6.82-6.76 (m, lH), 6.46-6.38 (m, lH), 6.04-5.94 (m, 
lH), 4.18-3.84 (m, 3H), 3.64-3.5 (m, lH), 3.12-2.82 (m, 
3H), 2.7-2.62 (m, lH), 2.56-2.24 (m, 4H), 2.27 (two s, 3H), 
2.2-2.1 (m, lH), 1.98-1.74 (m, 4H), 1.66-1.3 (m, 4H); 13C 
NMR (100 MHz, DMSO-d6 ) ll 174.6, 163.2 (163.18), 163.2 
(163.17), 163.1, 162.2, 157.1, 152.2 (152.23), 152.2 
(152.21), 138.7, 138.6, 132.5, 132.3, 132.1, 128.1, 126.7, 
121.3, 116.3, 115.1, 114.9, 103.7, 103.6, 100.8, 68.5, 67.1, 
66.9, 63.05, 62.98, 61.4, 60.8, 60.4, 60, 49.7, 34.8, 34.7, 30 
34.4, 28.64, 28.58, 27.6, 27.4, 25.2, 21.23, 21.15, 19.2. 
HRMS (ESI) Calcd for C33H360 5N2 Cl: 575.2318 (M+Ht. 
Found: 575.2312. Anal. Calcd. for C33H350 5 N2Cl1hH2 0: C, 
67.86; H, 6.21; N, 4.80. Found: C, 68.26; H, 6.41; N, 4.72. 
15 Ii 10.51 and 10.3 (two s, lH), 7.98 (d, lH, 1=8.7 Hz), 7.45 
(d, 2H, 1=8.3 Hz), 7.36-7.22 (m, lH), 7.28 (d, 2H, 1=8.3 Hz), 
7.02-6.93 (m, 2H), 6.8-6.64 (m, lH), 6.28 and 6.24 (two d, 
lH, 1=9 Hz), 6.07 and 6.02 (two d, lH, 1=6.8 Hz), 5.48-5.36 
(m, lH), 5.18-5.08 (m, lH), 4.3-4.36 (m, lH), 4.24-4.18 (m, 
20 lH), 4.16-4.08 (m, 2H), 3.9-3.8 (m, 2H), 3.78-3.4 (m, 16H), 
3.38-3.2 (m, 2H), 3.18-3.08 (m, 3H), 3.06-2.6 (m, 6H), 
2.54-2.02 (7H), 2-1.46 (m, 1 OH), 1.44-1.22 (m, 4H). MS 
(ESI): 1060 (M+H)+, 1077 (M+NH4)+, 1082 (M+Na)+, 
1098 (M+Kt. HRMS (ESI) Calcd for C54H710uN7 ClS: 
25 1060.4615 (M+H)+. Found: 1060.4612. 
35 
(1S,5S)-3-(2-Hydroxy-6-phenoxyhexyl)-3,4,5,6-
tetrabydro-l H-1,5-methanopyrido[ 1,2-a] [1,5]diazo-
cin-8(2H)-one (16) 
A mixture of phenol (2 g, 21.3 mmol), K2 C03 (8.8 g, 63.4 
mmol), and 6-bromo-1-hexene (3.4 mL, 25.5 mmol) in DMF 
(15 mL) was stirred at 60° C. for 5 h under a nitrogen 
atmosphere. The mixture was cooled, poured into water, and 
extracted with dichloromethane. The combined organic lay-
ers were washed successively with water and brine and dried 
over anhydrous MgS04 . The product was purified by col-
unm chromatography using ethyl acetate-hexanes (5:95) to 
afford 1.8 g (96%) of (hex-5-en-1-yloxy)benzene as color-
( 1 S,5 S )-3-( 6-( (3-( 4-Chloropheny 1)-2-methy 1-4-oxo-
4 H-chromen-7-yl)oxy )-2-oxohexyl)-3,4,5,6-tetra-
hydro- l H-1,5-methanopyrido[l ,2-a] [1,5]diazocin-8 
(2H)-one (14d) 
40 less oil: 1H NMR (400 MHz, CDC13 ) Ii 7.32-7.24 (m, 2H), 
6.96-6.86 (m, 3H), 5.9-5.76 (m, lH), 5.08-4.94 (m, 2H), 
3.96 (t, 2H, 1=6.5 Hz), 2.18-2.08 (m, 2H), 1.84-1.76 (m, 
2H), 1.62-1.52 (m, 2H); 13C NMR (100 MHz, CDC13 ) Ii 
To a suspension of Dess-Martin periodinane (520 mg, 1.2 
mmol) in dichloromethane (8 mL) was added a solution of 
13d (470 mg, 0.8 mmol) in dichloromethane (5 mL). The 
mixture was stirred at 25° C. for 2 h, diluted with dichlo- 45 
romethane, and washed with a 3:2 saturated solution of 
Na2 S203 and NaHC03 (20 mL. The combined organic layers 
were washed with brine and dried over anhydrous MgS04 . 
The product was purified by colunm chromatography using 
methanol-dichloromethane (1:98) to afford 380 mg (81 % ) of 50 
14d as a white foam: 1 H NMR ( 400 MHz, CDC13 ) Ii 8.1 ( d, 
lH, 1=8.8 Hz), 7.4 (d, 2H, 1=7.9 Hz), 7.32-7.2 (m, lH), 7.23 
(d, 2H, 1=7.9 Hz), 6.92 (d, lH, 1=8.8 Hz), 6.84-6.78 (m, lH), 
6.47 (d, lH, 1=8.8 Hz), 6 (d, lH, 1=6.8 Hz), 4.19 (d, lH, 
1=15.6 Hz), 3.97 (t, 2H, 1=5.2 Hz), 3.9 (dd, lH, 1=15.6, 6.8 55 
Hz), 3.2-2.86 (m, 4H), 2.74 (d, lH, 1=10.4 Hz), 2.62 (d, lH, 
1=10.8 Hz), 2.55 (d, lH, 1=10.8 Hz), 2.52-2.42 (m, lH), 2.29 
(s, 3H), 2.3-2.22 (m, lH), 2.18-2.06 (m, lH), 1.95 (d, lH, 
1=12.7 Hz), 1.82 (d, lH, 1=12.7 Hz), 1.7-1.52 (m, 4H); 13C 
NMR (100 MHz, CDC13 ) Ii 210.5, 176.1, 163.6, 163.5, 60 
162.9, 157.7, 151.2, 138.8, 133.8, 132, 131.8, 128.7, 127.6, 
122.4, 117.1, 116.9, 114.7, 104.8, 100.5, 68.2, 67.6, 60.8 
(60.83), 60.8 (60.76), 50.1, 39.1, 35.4, 28.5, 28.2, 25.4, 19.9, 
19.5. HRMS (ESI) Calcd for C33H340 5 N2 Cl: 573.2151 
(M+Ht. Found: 573.2156. Anal. Calcd. for 65 
C33H230 5 N2Cl1hH2 0: C, 68.09; H, 5.89; N, 4.81. Found: C, 
68.02; H, 5.95; N, 4.71. 
159.2, 138.7, 129.6, 120.6, 114.9, 114.6, 67.7, 33.6, 28.9, 
25.5. NMR data was consistent with reported data in CDC13 . 
A mixture of 77% meta-chloroperbenzoic acid (3.4 g, 15.3 
mmol) in dichloromethane (3 mL) was added dropwise to a 
solution of (hex-5-en-1-yloxy)benzene (1.8 g, 10.2 mmol) in 
dichloromethane (3 mL). The mixture was stirred at 25° C. 
for 2 h. The mixture was poured into saturated solution of 
NaHC03 and extracted with dichloromethane. The com-
bined organic layers were washed with brine, and dried over 
anhydrous MgS04 . The product was purified by colunm 
chromatography using ethyl acetate-hexanes (5:95) to afford 
1.6 g (81 %) of 2-(4-phenoxybutyl)oxirane as colorless oil: 
1H NMR (400 MHz, CDC13 ) ll 7.32-7.24 (m, 2H), 6.96-6.86 
(m, 3H), 3.98 (t, 2H, 1=6.3 Hz), 2.98-2.9 (m, lH), 2.78-2.72 
(m, lH), 2.52-2.46 (m, lH), 1.9-1.8 (m, 2H), 1.72-1.58 (m, 
4H); 13C NMR (100 MHz, CDC13 ) Ii 159.1, 129.6, 120.7, 
114.6, 67.6, 52.3, 47.2, 32.3, 29.2, 22.8. NMR data was 
consistent with reported data in CDCly A mixture of 2-( 4-
phenoxybutyl)oxirane (385 mg, 2 mmol) and cytisine (457 
mg, 2.4 mmol) in methanol (8 mL) was stirred in a pressure 
tube for 8 h at 90° C. The solvent was evaporated, and the 
product was purified by colunm chromatography using 
methanol-dichloromethane (ratio ranging from 2:98 to 7:93) 
to afford 750 mg (98%) of 16 as a mixture of diastereoiso-
US 10,188,743 B2 
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mers: 1H NMR (400 MHz, CDC13) Ii 7.32-7.22 (m, 3H), 
6.92 (t, lH, J=7.3 Hz), 6.89-6.84 (m, 2H), 6.44-6.4 (m, lH), 
6.01-5.94 (m, lH), 4.11 and 4.05 (two d, lH, J=15.5 Hz), 
3.96-3.84 (m, 3H), 3.62-3.46 (m, lH), 3.09-2.95 (m, 2H), 
2.88 and 2.83 (two d, lH, J=ll.1 and 10.7 Hz), 2.66-2.4 (m, 5 
3H), 2.36-2.06 (m, 3H), 1.97-1.67 (m, 4H), 1.64-1.22 (m, 
4H); 13C NMR (100 MHz, CDCl3) ll 163.4 (163.44), 163.4 
(163.42), 159.1, 150.9, 150.6, 138.9, 138.8, 129.5, 120.55, 
120.53, 117.03, 116.96, 114.52, 114.5, 104.8, 104.7, 67.64, 
67.63, 66.5, 65.9, 63.9, 63.5, 62.7, 62, 59.1, 58.9, 50.1, 50, 10 
35.8, 35.2, 34.5, 34.2, 29.4, 29.3, 28.3, 27.9, 26, 25.9, 22.2, 
22.1. HRMS (ESI) Calcd for C23H3i03N2 : 383.2329 
(M+H)+. Found: 383.2340. Anal. Calcd. for C33H20N20 3: 
C, 72.22; H, 7.91; N, 7.32. Found: C, 71.94; H, 7.93; N, 
7.28. 15 
( 1 S, 5S )-3-(2-oxo-6-phenoxyhexyl )-3,4, 5 ,6-tetra-
hydro- l H-1,5-methanopyrido[l ,2-a] [1,5]diazocin-8 
(2H)-one (17) 
To a suspension of Dess-Martin periodinane ( 424 mg, 1 
mmol) in dichloromethane (3 mL) was added a solution of 
20 
22 
prostate or colorectal cancer treatment an effective amount 
of a cytisine-linked isoflavonoid compound represented by 
formula (I): 
(I) 
8 
7 
N-L--w 6 '.t\r-(X)n 5 
0 
or pharmaceutically acceptable salt thereof or a pharma-
ceutical composition thereof, 
wherein Ar is an aryl or heteroaryl; n is an integer from 
1 to 5; each Xis independently a halide, or alkoxy, 
or more than one X on Ar together form a cyclic 
ether structure; and wherein the compound is sub-
stituted on the C-2 position with H, alkyl, cycloalkyl 
or alkoxy, substituted on the C-5, C-6, C-7, and C-8 
positions independently with H, hydroxy (OH), 
alkyl, cycloalkyl, alkoxy, Lis a substituted or unsub-
stituted di-radical linker group that links the cytisinyl 
group to either the C-5, C-6, C-7 or C-8 position. 
16 (258 mg, 0.7 mmol) in dichloromethane (3 mL). The 
mixture was stirred at 25° C. for 2 h, and the reaction was 
quenched with a 2:1 mixture of saturated Na2 S203 and 25 
NaHC03 (10 mL). The product was extracted with dichlo-
romethane. The combined organic layers were washed suc-
cessively with saturated NaHC03 solution and brine and 
dried over anhydrous MgS04 . The solvent was evaporated, 
and the product was purified by colunm chromatography 
using methanol-dichloromethane (1:24) to afford 147 mg 
2. The method of claim 1, wherein the compound is 
30 represented by of formula (II): 
( 57%) of 17 as a colorless, viscous oil: 1 H NMR ( 400 MHz, 
CDC13) ll 7.32-7.2 (m, 3H), 6.93 (t, lH, J=7.3 Hz), 6.9-6.84 
(m, 2H), 6.45 (d, lH, J=9 Hz), 5.98 (d, lH, J=6.8 Hz), 4.17 
(d, lH, J=15.5 Hz), 3.94-3.82 (m, 3H), 3.08-2.84 (m, 4H), 35 
2.72 (d, lH, J=l0.6 Hz), 2.62 (d, lH, J=l0.9 Hz), 2.58-2.51 
(m, lH), 2.5-2.42 (m, lH), 2.3-2.04 (m, 2H), 1.93 (d, lH, 
J=12.8 Hz), 1.8 (d, lH, J=12.8 Hz), 1.66-1.5 (m, 4H); 13C 
NMR (100 MHz, CDC13) Ii 210.6, 163.6, 159.1, 151.1, 
138.8, 129.5, 120.7, 116.9, 114.6, 104.8, 67.6, 67.4, 60.7 40 
(60.73), 60.7 (60.7), 50.1, 39.3, 35.5, 28.8, 28.2, 25.5, 20. 
HRMS (ESI) Calcd for C23H290 3N2 : 381.2173 (M+Ht. 
Found 381.2177. Removing traces of solvent from the 
viscous oil precluded obtaining a satisfactory combustion 
analysis of 17. An oxime derivative of 17 was prepared 45 
using 110 mg of 17, hydroxylamine hydrochloride (30 mg, 
0.4 mmole), and sodium acetate (39 mg, 0.5 mmol) in 
ethanol to afford 83 mg (72%) of a hygroscopic solid as 
mixture of syn/anti-isomers: mp 62-70° C. (recrystallized 
from diethyl ether-hexanes). Anal. Calcd. for 50 
C23H29N30 3.H20: C, 66.81; H, 7.56; N, 10.16. Found: C, 
66.93; H, 7.28; N, 10.07. 
Only the preferred embodiment of the present invention 
and examples of its versatility are shown and described in 
the present disclosure. It is to be understood that the present 55 
invention is capable of use in various other combinations 
and environments and is capable of changes or modifications 
within the scope of the inventive concept as expressed 
herein. Thus, for example, those skilled in the art will 
recognize, or be able to ascertain, using no more than routine 60 
experimentation, numerous equivalents to the specific sub-
stances, procedures and arrangements described herein. 
Such equivalents are considered to be within the scope of 
this invention, and are covered by the following claims. 
What is claimed is: 
1. A method of treating prostate or colorectal cancer, the 
method comprising administering to a patient in need of 
65 
(II) 
or pharmaceutically acceptable salt thereof or a pharma-
ceutical composition thereof. 
3. The method of claim 1, wherein Ar is a heteroaryl. 
4. The method of claim 3, wherein Ar is pyridinyl, 
diazinyl, pyrimidinyl, oxazolyl or imidazolyl. 
5. The method of claim 1, wherein the C-2 substituent is 
hydrogen Hor methyl; n is 1 or 2, Xis a halide or an alkoxy 
group or two X together form a cyclic ether structure; the 
C-5 substituent is H, hydroxy or alkoxy; the C-6 substituent 
is hydrogen H; the C-8 substituent is H, alkyl or substituted 
alkyl. 
6. The method of claim 2, wherein the C-2 substituent is 
hydrogen Hor methyl; n is 1 or 2, Xis a halide or an alkoxy 
group or two X together form a cyclic ether structure; the 
C-5 substituent is H, hydroxy or alkoxy; the C-6 substituent 
is hydrogen H; the C-8 substituent is H, methyl, alkyl or 
substituted alkyl. 
7. The method of claim 1, wherein Lis a diradical-R2-, 
-R2 Z-(R'2 )m -, or -R2Z(R'2 )m0-, where m is O or 1; 
R2 and R'2 are independently a C1_8 diradical alkyl, and Z 
represents either (CH2)n2 , -CH(OH)-, -CO-, ----C(O) 
0-, -OC(O)-, or -0-, wherein n2 is 1-4. 
8. The method of claim 2, wherein Lis a diradical-R2-, 
-R2 Z-(R'2 )m-, or -R2Z(R'2 )m0-, where mis O or 1; 
R2 and R'2 are independently a C1_8 diradical alkyl, and Z 
US 10,188,743 B2 
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represents either -(CH2 )n2-, ----CH(OH)-, -CO-, 
-C(O)O-, ---OC(O)-, or ---0-, wherein n2 is 1-4. 
* * * * * 
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